Estrella Immunopharma Inc ESLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.07
- Day Range
- $1.04–1.10
- 52-Week Range
- $0.86–33.00
- Bid/Ask
- $1.06 / $1.18
- Market Cap
- $39.54 Mil
- Volume/Avg
- 6,520 / 28,711
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.estrellabio.com
Valuation
|
Metric
|
ESLA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ESLA
|
|---|---|
Quick Ratio | 22.69 |
Current Ratio | 23.69 |
Interest Coverage | — |
Quick Ratio
ESLA
Profitability
|
Metric
|
ESLA
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tplrgcxrw | Qppxp | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mgzxmgqs | Kywzjlr | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gnprylgvj | Mwgpjr | $105.3 Bil | |
MRNA
| Moderna Inc | Kkxyshxpf | Nzw | $47.0 Bil | |
ARGX
| argenx SE ADR | Fytnqckpt | Thtb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rlbtlwz | Kpr | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tzfkfcvk | Jdytb | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ntlyqwx | Chsxj | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yjqkgltr | Cwvtfdw | $12.7 Bil | |
INCY
| Incyte Corp | Cfytnzwd | Yrvmcqc | $12.0 Bil |